HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Dietary Supplements Clinical Trials Coronavirus COVID-19

UK Trial Seeks ‘Definitive Answer' In Vitamin D's Role For COVID-19 Protection

  • News

Executive Summary

UK trial involving 5,000 participants "has the potential to give a definitive answer to the question of whether vitamin D offers protection against COVID-19," according to researchers.

You may also be interested in...



UK Government Backs Vitamin D COVID Benefits With Supplement Handout

By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

RB Shows Scholl The Door, While Welcoming In Biofreeze

Reckitt is refocusing its consumer health portfolio by offloading the troubled Scholl brand and acquiring fast-growing US topical analgesic Biofreeze.

Table

View full table

Topics

Tags:
Dietary Supplements Clinical Trials Coronavirus COVID-19
UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By